Richter Gedeon accepts FYLREVY filing and Richter Gedeon stock costs EUR 34.73

Published on 10/19/2026 at 09:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 3.00 percent to HUF 151.8 billion in 2026. Richter Gedeon stock costs EUR 34.73 on October 19, 2026 at Lang & Schwarz.

Pipeline and earnings context

Richter received U.S. filing acceptance for FYLREVY on October 14, 2026.
First-half 2026 revenue rose 3.00 percent to HUF 151.8 billion.
Richter Gedeon stock trades at EUR 34.73 at 9:15 a.m. CEST at Lang & Schwarz on October 19, 2026.

Richter Gedeon, HU0000123096, Illustration mit AI erstellt.

Richter Gedeon (ISIN HU0000123096) was trading at EUR 34.73 at Lang & Schwarz on October 19, 2026 at 9:15 a.m. CEST in pre-market trading. The company had received U.S. filing acceptance for its FYLREVY application on October 14, 2026, according to Gedeon Richter.

FYLREVY moves into U.S. review

The filing acceptance moves FYLREVY into the U.S. regulatory review process. That gives investors a concrete pipeline milestone alongside Richter Gedeon's established pharmaceutical business.

The October 14 announcement is the latest dated company event in the available reporting window. The announcement identifies FYLREVY as a new drug application, but it does not disclose a sales value or a launch date.

What supports the earnings picture?

Richter Gedeon entered the filing decision with stronger first-half operating momentum. In the first half of 2026, revenue reached HUF 151.8 billion, an increase of 3.00 percent from the comparable period, according to Yahoo Finance.

The same earnings-call material said constant-currency revenue growth was 8.70 percent in the first half of 2026. Constant-currency Clean EBIT increased 21.00 percent, while management upgraded 2026 pharma Clean EBIT expectations to double-digit constant-currency growth. These figures point to operating improvement even as reported revenue was affected by foreign-exchange effects.

Pipeline meets operating momentum

For investors, the filing and the first-half figures describe two different parts of the story. FYLREVY provides a regulatory milestone, while the H1 2026 figures show the operating base supporting Richter Gedeon's pharmaceutical strategy. The next useful test is whether the company can convert that operating momentum into further progress across its pipeline and profitability measures.

At Lang & Schwarz, Richter Gedeon was trading at EUR 34.73 on October 19, 2026 at 9:15 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Richter Gedeon stock.